Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of FTY720 combined with cyclosporine and corticosteroids in patients receiving a kidney transplant.

• Phase: Phase 2

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Fingolimod Hydrochloride

Criteria

Inclusion Criteria

• Completion of Core study

Exclusion Criteria

Other protocol-defined exclusion criteria may apply.